Literature DB >> 27590364

Performance-Based Contingency Management in Cognitive Remediation Training: A Pilot Study.

Brian D Kiluk1, Matthew B Buck2, Kathleen A Devore2, Theresa A Babuscio2, Charla Nich2, Kathleen M Carroll2.   

Abstract

Impairments in attention, working memory, and executive function are common among substance users and may adversely affect SUD treatment outcomes. The ability of cognitive remediation (CR) interventions to improve these deficits is hindered in part because levels of engagement in CR training may be inadequate to achieve benefit. This pilot study aimed to increase CR engagement and improve outcome by implementing contingency management (CM) procedures that reinforce performance improvements on CR tasks. Participants were forty individuals (50% male; 65% African American) in an outpatient substance use treatment facility with mild cognitive impairment who had ≥30-days of abstinence from alcohol and drugs. They were randomized to standard (CR-S; n=21) or CM-enhanced (CR-CM; n=19) cognitive remediation training. CR consisted of 1-hour sessions, three times per week for four weeks (12 sessions). A neuropsychological assessment battery was administered prior to and after the four-week intervention. Both groups had high rates of CR session attendance (mean CR-S=11.7, CR-CM=10.9 sessions). Performance on 8 of the 9 CR tasks significantly improved over time for both conditions, with the CR-CM condition demonstrating greater improvement on a CR Sequenced Recall task [F(1,37)=5.81, p<.05]. Significant improvement was also evident on 4 of 9 neuropsychological assessment measures, with the CR-CM condition showing differential improvement on the Trail Making Test - Part B [F (1,37)=5.34, p<.05]. These findings support the feasibility of using CM procedures to enhance substance users' engagement with CR training and suggest the potential value of more research in this area.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognitive remediation; Contingency management; Substance use disorders

Mesh:

Year:  2016        PMID: 27590364      PMCID: PMC5154814          DOI: 10.1016/j.jsat.2016.08.003

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  64 in total

1.  Dose-related neurobehavioral effects of chronic cocaine use.

Authors:  K I Bolla; R Rothman; J L Cadet
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1999       Impact factor: 2.198

2.  Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART).

Authors:  C W Lejuez; Jennifer P Read; Christopher W Kahler; Jerry B Richards; Susan E Ramsey; Gregory L Stuart; David R Strong; Richard A Brown
Journal:  J Exp Psychol Appl       Date:  2002-06

3.  Normative data for elderly African Americans for the Stroop Color and Word Test.

Authors:  Robert G Moering; John A Schinka; James A Mortimer; Amy Borenstein Graves
Journal:  Arch Clin Neuropsychol       Date:  2004-01       Impact factor: 2.813

4.  Speed and memory in the WAIS-III Digit Symbol--Coding subtest across the adult lifespan.

Authors:  Stephen Joy; Edith Kaplan; Deborah Fein
Journal:  Arch Clin Neuropsychol       Date:  2004-09       Impact factor: 2.813

Review 5.  Cognitive impairment in substance abuse.

Authors:  Peter W Vik; Tony Cellucci; Amy Jarchow; Jill Hedt
Journal:  Psychiatr Clin North Am       Date:  2004-03

6.  Performance on the Stroop predicts treatment compliance in cocaine-dependent individuals.

Authors:  Chris C Streeter; Devin B Terhune; Theodore H Whitfield; Staci Gruber; Ofra Sarid-Segal; Marisa M Silveri; Golfo Tzilos; Maryam Afshar; Elizabeth D Rouse; Hua Tian; Perry F Renshaw; Domenic A Ciraulo; Deborah A Yurgelun-Todd
Journal:  Neuropsychopharmacology       Date:  2007-06-13       Impact factor: 7.853

7.  Computer-assisted cognitive rehabilitation for the treatment of patients with substance use disorders: a randomized clinical trial.

Authors:  William Fals-Stewart; Wendy K K Lam
Journal:  Exp Clin Psychopharmacol       Date:  2010-02       Impact factor: 3.157

Review 8.  Cognitive remediation in schizophrenia.

Authors:  Alice Medalia; Jimmy Choi
Journal:  Neuropsychol Rev       Date:  2009-05-15       Impact factor: 7.444

9.  The trail making test, part B: cognitive flexibility or ability to maintain set?

Authors:  Kathleen Bechtold Kortte; Michael David Horner; Whitney K Windham
Journal:  Appl Neuropsychol       Date:  2002

Review 10.  Thinking about the future cognitive remediation therapy--what works and could we do better?

Authors:  Til Wykes; Will D Spaulding
Journal:  Schizophr Bull       Date:  2011-09       Impact factor: 9.306

View more
  6 in total

Review 1.  Contingency Management: New Directions and Remaining Challenges for An Evidence-Based Intervention.

Authors:  Carla J Rash; Maxine Stitzer; Jeremiah Weinstock
Journal:  J Subst Abuse Treat       Date:  2016-09-28

2.  Working memory training and high magnitude incentives for youth cannabis use: A SMART pilot trial.

Authors:  Catherine Stanger; Emily A Scherer; Hoa T Vo; Steven F Babbin; Ashley A Knapp; James R McKay; Alan J Budney
Journal:  Psychol Addict Behav       Date:  2019-06-27

3.  Connectome-Based Prediction of Cocaine Abstinence.

Authors:  Sarah W Yip; Dustin Scheinost; Marc N Potenza; Kathleen M Carroll
Journal:  Am J Psychiatry       Date:  2019-01-04       Impact factor: 18.112

Review 4.  Neuropsychological Interventions for Decision-Making in Addiction: a Systematic Review.

Authors:  Antonio Verdejo-García; Miguel A Alcázar-Córcoles; Natalia Albein-Urios
Journal:  Neuropsychol Rev       Date:  2018-09-26       Impact factor: 7.444

Review 5.  Cognition and addiction
.

Authors:  Antonio Verdejo-Garcia; Gloria Garcia-Fernandez; Geert Dom
Journal:  Dialogues Clin Neurosci       Date:  2019-09       Impact factor: 5.986

6.  Executive Function and Contingency Management in Methamphetamine Use Disorder.

Authors:  Lara J van Nunen; Marilyn T Lake; Jonathan C Ipser; Dan J Stein; Steven J Shoptaw; Edythe D London
Journal:  J Alcohol Drug Depend       Date:  2021-05-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.